Finance

Lists
AGMB:NASDAQ
Agomab Therapeutics NV
6,85 USD
0,00%
(0,00) 1D
4-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGMB...
Open
7,00 USD
High
7,08 USD
Low
6,76 USD
Mkt. cap
337,35 млн
Avg. vol.
140,70 миң
Volume
0,00
52-wk high
17,82 USD
52-wk low
6,55 USD
No. of employees
62
Open
7,00 USD
High
7,08 USD
Low
6,76 USD
Mkt. cap
337,35 млн
Avg. vol.
140,70 миң
Volume
0,00
52-wk high
17,82 USD
52-wk low
6,55 USD
No. of employees
62
News stories
From web sources and news partners
About Agomab Therapeutics NV
CEO-
Employees62
Founded2017
Headquarters-
SectorPharmaceutical industry
Industry-
Websiteagomab.com
Analyst ratings
Based on 6 analysts giving stock ratings to AGMB in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AGMB in the last 3 months.
Highest
Current 6,85 USD
60,00 USD (+775,91%)
Average
35,20 USD (+413,87%)
Lowest
17,00 USD (+148,18%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ulz
Morgan Stanley
Buy
Reiterated
28,00 USD
+308,8%
11/02/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
35,00 USD
+410,9%
10/20/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
28,00 USD
+308,8%
10/19/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
60,00 USD
+775,9%
10/14/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
36,00 USD
+425,5%
10/02/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
09/14/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
17,00 USD
+148,2%
08/19/2026
William Wood
B. Riley Securities
Buy
Initiated
34,00 USD
+396,4%
07/23/2026
Thomas Smith
Leerink Partners
Buy
Initiated
36,00 USD
+425,5%
03/03/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. июн.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11,01 млн
13,86 млн
11,48 млн
11,48 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,34 млн
3,17 млн
6,09 млн
6,09 млн
Operating expense
13,70 млн
16,53 млн
17,03 млн
17,03 млн
Total operating expenses
13,70 млн
16,53 млн
17,03 млн
17,03 млн
Operating income
-13,70 млн
-16,53 млн
-17,03 млн
-17,03 млн
Other non operating income
-128,00 миң
-1,54 млн
-219,00 миң
-219,00 миң
EBT including unusual items
-13,43 млн
-17,40 млн
-15,49 млн
-15,49 млн
EBT excluding unusual items
-13,43 млн
-17,40 млн
-15,49 млн
-15,49 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-656,00 миң
-506,00 миң
-539,50 миң
-539,50 миң
Net income
-13,43 млн
-17,40 млн
-15,49 млн
-15,49 млн
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
427,50 миң
720,00 миң
1,87 млн
1,87 млн
Interest expense
-37,50 миң
-
-107,50 миң
-107,50 миң
Net interest expenses
390,00 миң
720,00 миң
1,76 млн
1,76 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,60 млн
-16,51 млн
-16,94 млн
-16,94 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору